J&J Is Using Two Tecvayli Trials to Own Myeloma’s First Relapse Whether or Not Patients Had Darzalex
J&J’s frontline success with Darzalex is manufacturing the monotherapy market for Tecvayli at first myeloma relapse.
By therapy area
Henlius Licensed a US pH-Switch Platform for Two T-Cell Engager Targets Without Disclosing Any Payment
Henlius bought a switch, not a molecule, and the deal discloses no dollar figure at all, not even a headline total.
Roche Claims Best-in-Class Potential for Sefaxersen Without Disclosing How Much It Cut Proteinuria
Sefaxersen hits the same target as Novartis’s Fabhalta. Roche withheld the one number that would show which drug does more.
Boehringer’s $1 Billion Cancer Deal Will Pay to Put Envisagenics’ ALS Drug Into the Clinic
Boehringer is buying options on cancer targets. Envisagenics plans to spend the money taking an ALS drug into the clinic.
Beacon Succeeded in XLRP Where Biogen and J&J Failed, on an Endpoint Neither of Them Used
QuickCI read/Ophthalmology/Cell & Gene Tx Beacon Succeeded in XLRP Where Biogen and J&J Failed, on an Endpoint Neither of Them Used Athithi Verma· 22 September 2026· 2 min read· Synopulse Beacon Therapeutics said on 21 September 2026 that laru-zova met the FDA-endorsed primary endpoint of VISTA, a 12-month randomised trial in 85 males aged 12 … Read more
Brazil Approved AstraZeneca’s Camizestrant 17 Days After the FDA, Whose Own Advisers Had Voted Against It
Every major regulator has now said yes to a strategy the FDA’s advisers doubted. The constraint is a blood test.
Novartis’s $900 Million BoomRay Licence Names No Target, No Isotope and No Upfront
Without an upfront, a target or an isotope, BoomRay’s $900 million headline is a ceiling rather than a valuation.
Caplyta Doubled the Mania Response Rate, and Only Dry Mouth and Nausea Cleared J&J’s Side Effect Bar
The efficacy is the headline. The competitive case sits in the side effect line, and it points at AbbVie’s Vraylar.
A Custom ALS Drug Took Three Years to Build and One Year to Normalise One Man’s Neurofilament
Built in about three years for one mutation, it normalised a biomarker in one man. A larger cohort sits outside the paper.
China Ordered Rare Disease Clinics in Every Province by December and Left Payment Out
Every instruction raises the number of diagnosed patients. None addresses what they can be prescribed, or who pays.